MedPath

Tagged News

Shuttle Pharmaceuticals Signs $10 Million Letter of Intent to Acquire AI Drug Discovery Platform Molecule.ai

AIDrug DiscoveryOncology
  • Shuttle Pharmaceuticals Holdings announced a non-binding letter of intent to acquire Molecule.ai for $10 million in cash and stock, subject to milestone completion.
  • Molecule.ai's AI platform leverages machine learning models and large language models to accelerate drug discovery through molecular property prediction and drug-target interaction modeling.
  • The acquisition aims to integrate advanced AI capabilities including autonomous workflow features that could reduce development timelines and costs for therapeutic candidates.
  • The deal positions Shuttle to expand beyond its current focus on radiation therapy treatments for cancer patients into broader AI-driven drug discovery applications.

Cognivia Launches AI-Powered Dashboard to Predict Clinical Trial Dropout and Placebo Response in Real-Time

AI
  • Cognivia Signal, the world's first real-time behavioral risk intelligence dashboard, uses AI to predict clinical trial participant dropout and placebo response patterns.
  • Early validation in a Type 1 Diabetes trial demonstrated 93% accuracy in predicting participant dropout before it occurred.
  • The platform integrates proprietary questionnaires with machine learning algorithms to help sponsors reduce trial delays and improve study performance.
  • Clinical trial dropout and placebo response cost sponsors millions annually through delayed timelines and patient replacement costs.

Zimmer Biomet Completes $177 Million Acquisition of Monogram Technologies to Pioneer Autonomous Orthopedic Robotics

AI
  • Zimmer Biomet has completed its $177 million acquisition of Monogram Technologies, an AI-driven orthopedic robotics company, creating the broadest portfolio of orthopedic robotics and navigation technologies.
  • Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027.
  • The acquisition positions Zimmer Biomet to become the first orthopedic company to offer a fully autonomous robotic solution, with Monogram beginning clinical studies for the fully autonomous version in July 2025.
  • The transaction includes contingent value rights entitling shareholders to receive up to $12.37 in additional cash if certain product development, regulatory and revenue milestones are achieved through 2030.

Peer AI Secures $12.1M to Transform Drug Approval Process with Specialized AI Platform

AI
  • Peer AI raised $12.1 million in funding led by Flare Capital Partners and SignalFire to accelerate drug approvals through its agentic AI platform for regulatory documentation.
  • The company's specialized AI agents combined with human oversight reduce document drafting times by 55-94%, cutting clinical study report preparation from 40 to 17 days and protocol turnaround from 6-8 weeks to one week.
  • Regulatory documentation represents a major bottleneck in drug development, requiring over 200,000 pages across 1,500 documents per drug, with nearly one-third of FDA submissions having quality issues leading to 435-day delays.
  • The platform addresses a $15 billion market opportunity and has demonstrated strong adoption with daily active use growing 3X and overall platform volume increasing 6X in the first three quarters of 2025.

Ryght AI Forms Scientific Advisory Board to Advance AI-Powered Clinical Trial Technology

AIOncology
  • Ryght AI announces formation of inaugural Scientific Advisory Board comprising 12 globally recognized experts in oncology, hematology, dermatology, and AI to guide clinical trial innovation.
  • The board will oversee development of AI Site Twin technology, which creates dynamic digital replicas of research facilities to transform site selection and trial operations.
  • Advisory board members emphasize the platform's potential to accelerate patient recruitment and streamline workflows, bringing therapies to market months or years ahead of schedule.
  • The technology addresses longstanding challenges in clinical trial feasibility by replacing static, outdated data with real-time insights powered by generative AI.

Form Bio and Cure Rare Disease Partner to Accelerate Gene Therapy Development for Duchenne Muscular Dystrophy

AIRare Disease
  • Form Bio and Cure Rare Disease announced a strategic partnership to accelerate genetic medicine development for rare neuromuscular diseases, beginning with Duchenne muscular dystrophy.
  • Form Bio's AI-powered platform improved AAV therapeutic yield from 13% to 59% in just one month by optimizing the promoter and nuclease components.
  • The collaboration aims to streamline lead candidate selection and reduce development costs while advancing treatments for patients with devastating neuromuscular diseases that currently lack options.
  • The partnership demonstrates how AI-driven genome engineering can enhance gene therapy manufacturability and reduce clinical development risks.

Algen Biotechnologies Partners with AstraZeneca in $555M AI-Driven Drug Discovery Deal for Immunology Targets

AIDrug Discovery
  • Algen Biotechnologies announced a multi-target partnership with AstraZeneca worth up to $555 million to accelerate discovery of novel therapeutic targets in immunology using AI-powered drug discovery.
  • The collaboration will leverage Algen's AlgenBrain™ platform, which combines CRISPR gene modulation with artificial intelligence to identify disease targets through single-cell gene modulation and causal disease trajectory mapping.
  • AstraZeneca will receive exclusive rights to develop and commercialize therapies against targets identified through the partnership, while Algen receives upfront payments and milestone-based compensation.
  • The AlgenBrain™ platform models disease progression by capturing billions of dynamic RNA changes in human disease-relevant cell types, aiming to improve translational accuracy and clinical success probability.

Roche Receives CE Mark for First AI-Based Kidney Risk Assessment Tool

AI
  • Roche has received CE mark approval for the Kidney KlinRisk Algorithm, the first AI-based risk stratification tool to assess progressive decline in kidney function, developed in collaboration with KlinRisk Inc.
  • The algorithm will be integrated into Roche's comprehensive chronic kidney disease (CKD) algorithm panel on the navify Algorithm Suite to support care across all stages of CKD, which affects more than 700 million people worldwide.
  • The machine learning-based tool combines multiple input factors from routine blood and urine tests to predict CKD before symptom onset, particularly targeting adults with diabetes or hypertension who are at elevated risk for kidney function decline.
  • The CKD algorithm panel is now available in Europe and the United Kingdom, with planned launches in the United States, Middle East, and Asia to help clinicians make more informed decisions about kidney function management.

AI-Guided Discovery of Enterololin Offers New Hope for IBD Treatment

AIDrug Discovery
  • Researchers at McMaster University and MIT have discovered enterololin, a narrow-spectrum antibiotic that specifically targets disease-causing bacteria in inflammatory bowel diseases while preserving beneficial gut microbiome.
  • The breakthrough utilized AI to predict the drug's mechanism of action in just six months for $60,000, compared to traditional methods that typically require two years and $2 million.
  • Enterololin targets the Enterobacteriaceae family including E. coli strains that drive Crohn's disease, offering a promising treatment option for millions of IBD patients who currently have no cure.
  • Stoked Bio has licensed the drug and aims to begin human trials within three years, with early results showing promise against other drug-resistant bacteria like Klebsiella.

Wearable Heart Rate Variability Patch Reduces Substance Use by 64% in Recovery Patients

AI
  • Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.
  • The phase 2 clinical trial of 115 adults with severe substance use disorder showed participants were 64% less likely to use substances when wearing the AI-powered smart patch.
  • The Lief HRVB Smart Patch detects stress and cravings through heart rate variability monitoring and prompts users to perform breathing exercises for real-time intervention.
  • Results published in JAMA Psychiatry represent a breakthrough in non-pharmacological approaches to addiction recovery during the critical first year of treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.